Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.
You may also be interested in...
Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.
An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.
China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.